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Abstract 
Background: The prevalence of esophageal atresia (EA) has been shown to vary across and within 
different geographical settings. Investigation of geographical differences may also provide an 
insight into the underlying aetiology of EA.  
Methods: The study population comprised infants diagnosed with EA in 1998-2007 from 18 of the 
46 birth defects surveillance programs, all of which are members of the International Clearinghouse 
for Birth Defects Surveillance and Research (ICBDSR). Total prevalence per 10,000 births for EA 
was defined as the total number of cases in live births, stillbirths, and elective termination of 
pregnancy for fetal anomaly (ETOPFA) divided by the total number of all births in the population. 
Results: Among the participating birth defects surveillance programs, a total of 2,943 cases of EA 
were diagnosed between 1998 and 2007 with an average prevalence of 2.44 (95% CI 2.35, 2.53) per 
10,000 births, ranging  between 1.77 and 3.68 per 10,000 births. Of all infants diagnosed with EA, 
there were 2,761 (93.8%) live births, 82 (2.8%) stillbirths, 89 (3.0%) ETOPFA, and 11 (0.4%) 
unknown outcomes. The majority of cases (2,020, 68.6%), had a reported esophageal atresia with 
fistula, 749 cases (25.5%) were without fistula, and 174 cases (5.9%) were registered with an 
unspecified code. 
Conclusions: On average, EA affected 1 in 4,099 births (95% CI: 1 in 3,954-4,251 births) with the 
prevalence varying across and within different geographical settings, but relatively consistent over 
time and comparable between surveillance programs. Findings suggest differences in the prevalence 
observed between programs are likely to be attributable to variability in the ethnic composition or 
issues in reporting and/ or registration procedures of EA, rather than a real risk occurrence 
difference per se. 
 
Key words: esophageal atresia, congenital anomalies, prevalence, epidemiology, 
 
 
 
 
 
 
 
 
 
 
 5 
 
Introduction 
Esophageal atresia (EA) is the most frequent anomaly of the esophagus and is characterised by the 
complete discontinuity of the esophagus with or without an abnormal connection between the 
esophagus and the trachea, tracheo-esophageal fistula (TEF). Infants are diagnosed either prenatally 
or, in most cases, at birth and require surgical repair in the first few days of life. Although the 
aetiology of EA is largely unknown (Felix et al., 2009) geographic, temporal and ethnic variations 
have been reported.  
 
The prevalence of EA has been shown to vary across and within different geographical settings with 
a study from five regions in Britain reporting rates ranging between 0.7 and 3.2 per 10,000 births 
(Rankin et al., 2005) although EA cases in that study also included those with esophageal stenosis. 
Similarly, differences in rates among areas in the United States have been reported with a 
prevalence of 2.24 in Hawaii (Forrester and Merz, 2005), 2.33 in Texas (Ethen and Canfield, 2002) 
and 2.82 per 10,000 births in California (Torfs et al., 1995); among  European countries, prevalence 
has been reported for Iceland (1.83 per 10,000) (Gunnarsdottir et al., 2004), France Strasbourg (2.96 
per 10,000) (Stoll et al., 2009), and UK Northern Region (3.13 per 10,000 births) (Sparey et al., 
2000). Given EA is a rare condition, small numbers may also have a potential impact on rates. 
Ethnic composition of a population may also influence EA prevalence with lower rates noted 
among Hispanic and African-American communities (Carmichael et al., 2004; Forrester and Merz, 
2005).  
 
International differences in the prevalence of EA across different geographical regions may also be 
attributable to differences in case identification methods, case definition, and case ascertainment.  
Best estimates of prevalence of major birth defects, based on international data, are important to 
serve as a reference point for the evaluation of individual, regional or national surveillance 
programs and to identify geographical regions of higher or lower than expected prevalence 
(Leoncini et al., 2008; Cocchi et al., 2010). Investigation of geographical differences may also 
provide an insight into the underlying aetiology of EA. The aim of this study was to investigate the 
international prevalence of EA among birth defects surveillance programs (BDSP) in North and 
South America, Europe and Australia and provide a worldwide collective estimate. 
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Materials and methods  
Data for this study were sourced from 18 birth defects surveillance programs, all members of the 
International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR).  Programs who 
agreed to participate provided relevant data on EA among live births, stillbirths and elective 
termination of pregnancy for fetal anomaly (ETOPFA), if permitted. All participating programs 
were also required to have a stable methodology of ascertainment and/or registration over the 10-
year study period, 1998-2007. The following programs provided data for slightly different years: 
Slovak Republic 2001-2007, USA Texas 1997-2006, USA Utah 1999-2007.  
 
The main characteristics of the 18 participating programs in this study are reported in Table 1 with 
additional details available from the annual reports of the ICBDSR (www.icbdsr.org) (ICBDSR, 
2008) and the National Birth Defects Prevention Network (www.nbdpn.org) (NBDPN, 2008), and 
from selected publications from individual programs (Mutchinick et al., 1988; Czeizel, 1997; 
Correa-Villasenor et al., 2003; Castilla and Orioli, 2004; De Vigan et al., 2005; Feldkamp et al., 
2005; Bower et al., 2009; Lowry RB et al., 2009).  
 
Classification of cases was undertaken by each individual program using either the British 
Paediatric Association International Classification of Diseases (ICD) coding system (ICD9-BPA) or 
ICD10. For this study, EA cases included all reported infants and fetuses diagnosed with an 
esophageal atresia with TEF (ICD9-BPA: 750.31, 750.33; ICD10: Q39.1) or without TEF (ICD9-
BPA: 750.30; ICD10: Q39.0) or unspecified EA (750.3). Other types of EA including TEF without 
atresia (ICD9-BPA: 750.32; ICD10: Q39.2), esophageal stenosis or esophageal web (ICD9-BPA: 
750.34, 750.35; ICD10: Q39.3, Q39.4) were considered separately. 
 
Total prevalence per 10,000 births was defined as the total number of cases among live births, 
stillbirths, and ETOPFA divided by the total number of all births (livebirths and stillbirths) in the 
population. We used the term “total prevalence” instead of “prevalence” or “birth prevalence” to 
underline that ETOPFA were also included. To validate the total prevalence we undertook a 
sensitivity analysis by comparing overall total prevalence to estimated result for six programs 
previously shown to have good ascertainment of birth defects (Leoncini et al., 2010). Ninety-five 
percent confidence intervals for prevalence were calculated based on the Poisson distribution. Chi-
square test for trend was used to evaluate homogeneity and time trend of the prevalence in the study 
period. Statistical analyses were performed using Stata 9.0 (Stata Corporation, College Station, TX, 
USA) and SAS 9.1 (SAS Institute Inc, Cary, NC), with P-values<0.05 considered statistically 
significant. 
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Results 
Among the eighteen surveillance programs of the ICBDSR a total of 2,943 cases of EA were 
registered between 1998 and 2007 (Table 2). The majority of cases (2,020, 68.6%) had a reported 
esophageal atresia with fistula, 749 cases (25.5%) were without fistula and 174 cases (5.9%) were 
unspecified. The total prevalence of EA was 2.44 (95% CI 2.35-2.53) per 10,000 births; and on 
average, EA affected 1 in 4,099 births (95% CI: 1 in 3,954 - 4,251 births). The prevalence ranged 
from 1.77 (95% CI 1.52-2.06) per 10,000 births in Hungary and Atlanta to 3.68 (95% CI 3.41-3.97) 
in South America (Table 2). Sensitivity analysis utilising data from programs with optimal 
ascertainment of cases revealed total prevalence of EA was 2.47 per 10,000 births. 
 
Overall, the average annual trend in EA remained fairly constant over the study period varying 
between 2.32 in 1998 to 2.60 per 10,000 births in 2007, and there was no evidence of a significant 
linear trend in EA among each of the programs (data not shown). However, there was a modest 
decline in the trend of EA in Alberta and Dublin; and a slight rise in cases in Western Australia, 
Mexico and Israel.  
 
Of all infants diagnosed with EA, there were 2,761 (93.8%) live births, 82 (2.8%) stillbirths, 89 
(3.0%) ETOPFA and 11 (0.4%) with unspecified outcome. Programs in Dublin and Alberta had a 
relatively higher proportion of stillbirths (14.0% and 11.4%, respectively) and in the case of 
ETOPFA, two programs (Central East, France and Wales) reported one in five cases that resulted in 
a termination of pregnancy (Figure 1). Excluding ETOPFA, the total prevalence of EA reduced 
slightly to 2.37 (95% CI 2.28-2.45) per 10,000 births.  
 
The total prevalence of TEF without atresia was 0.22 per 10,000 births (95%CI 0.19-0.24) (1 in 
every 46,398 births). Compared to EA, it was reported much less frequently (less than 0.5 per 
10,000 births) by all members of ICBDSR except for Western Australia, where the prevalence was 
1.3 per 10,000 births. Cases of esophageal stenosis or esophageal web (n=44) occurred rarely, 1 in 
every 274,170 births (0.04 per 10,000 births), but was more commonly diagnosed in Saxony–
Anhalt, Germany (0.12 per 10,000 births) compared with all other surveillance programs. 
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Discussion 
Esophageal atresia affects, on average, 1 in every 4,099 births, with a total prevalence of 2.44 
(95%CI 2.35-2.53) per 10,000 births among 18 birth defects surveillance program members of the 
ICBDSR. The prevalence ranged between 1.77 and 3.68 per 10,000 births among members 
representing North and South America, Europe and Australia. However, sensitivity analysis limiting 
data to member programs with optimal case ascertainment revealed an almost identical total 
prevalence (2.47) and findings are also similar to an earlier study of EA among nine ICBDSR 
programs reporting a prevalence of 2.56 per 10,000 births from 1965 to 1989 (Robert et al., 1993).  
 
Findings from other congenital anomaly surveillance programs such as EUROCAT, the European 
surveillance of congenital anomalies working group, reported a comparable prevalence of 2.46 per 
10,000 births among 23 member registries for the years 1997-2006 (Pedersen et al., 2012). This 
analysis included five ICBDSR members from our present study; and when limiting our data to 10 
European members of the ICBDSR, we also found the same result (2.44 per 10,000 births). The 
estimated national prevalence of EA reported by the US National Birth Defects Prevention Network 
was 2.12 per 10,000 births (adjusted for race/ ethnicity) among 14 member programs for the period 
from 2004-2006. Slight differences in prevalence by case ascertainment methods were observed 
with results ranging from 2.17 among 10 programs using active birth defects surveillance to 2.36 
among seven passive surveillance systems and 2.54 among five passive surveillance programs with 
a case confirmation component (Parker et al., 2010). 
 
Despite the range of geographic locations and study periods, comparison of the total prevalence of 
EA by various international surveillance programs reveals relatively similar results with EA 
diagnosed among 1 in 4,099 to 4,608 infants. These findings highlight the relative stability of the 
prevalence of EA, internationally and over time. In our international study there was no consistent 
trend for neighbouring countries or states within continents, with small variability in prevalence 
potentially influenced by chance or differences in reporting or surveillance methods, study 
population, ethnic distribution, geographical or environmental factors. For example, the two 
programs reporting higher prevalence of EA may be explained by their hospital-based case 
ascertainment program with active notification by trained clinicians in each hospital. However, 
higher prevalence may also reflect a truly higher rate of EA and further investigation of these results 
is important. Conversely, slightly lower prevalence of EA reported from surveillance programs in 
USA Atlanta and USA Texas may be explained by the ethnic composition of the population in these 
two US states, with almost two-thirds of all infants born to African-American or Hispanic women, 
respectively (NBDPN, 2009). Studies of congenital malformations by ethnic groups in the US have 
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found that compared with non-Hispanic white women, Hispanic and African-American women had 
a reduced risk of EA without fistula (relative risk (RR) 0.75; 95%CI 0.62 – 0.90) and RR 0.59; 95% 
CI 0.62-0.90; respectively) (Carmichael et al., 2004; Forrester and Merz, 2005). In Hungary, a 
combination of incomplete registration of cases at birth and terminations of pregnancy, and a true 
lower prevalence may explain their lower rates. 
  
Although there was some discrepancy among programs in the distribution of specific types of EA 
(with and without TEF), the overall proportions were similar to that reported in the literature (Clark, 
1999; Shaw-Smith, 2006; Spitz, 2007). These differences may be due to variation in classification, 
identification or reporting practices across programs rather than reflect real differences (Shaw-
Smith, 2006; Spitz, 2007). Higher prevalence of TEF without atresia in some settings may also be 
due to increased detection and sources of notification such as post-mortem evaluation (Bower et al., 
2009). Several factors may also influence reporting and registration of EA including: screening 
policies and procedures, clinician skills, timing of aneuploidy and fetal anomaly screening, 
subsequent availability and timing of elective termination of pregnancy, and autopsy policies. 
Previous studies have shown that the rate of termination of pregnancy is higher for cases with 
chromosomal or additional congenital anomalies than for cases with an isolated anomaly (Haeusler 
et al., 2002; Garne et al., 2007). Chromosomal anomalies have been reported to occur in 6-10% of 
EA cases (Garne et al., 2007; Genevieve et al., 2007; Pedersen et al., 2012); while greater than 50% 
and up to two-thirds of infants with EA have additional anomalies (Genevieve et al., 2007; Spitz, 
2007; de Jong et al., 2010a; Pedersen et al., 2012;). Given EA is more likely to be diagnosed in 
conjunction with other syndromes (particularly VACTERL) or chromosomal anomalies that may 
result in termination of pregnancy, it is important to include terminated cases in ascertainment 
(Shaw-Smith, 2006; Felix et al., 2009). For some anomalies, availability and reporting of ETOPFA 
may increase ascertainment of cases. In this study, total prevalence of EA was only slightly 
attenuated to 2.37 per 10,000 births if terminations were excluded. This finding was confirmed by a 
study from Texas which found no impact on rates of EA when elective terminations before 20 
weeks gestation were included in case ascertainment (Ethen and Canfield, 2002).  
 
The underlying aetiology of EA has been described as multifactorial and is likely to differ across 
settings (Robert et al., 1993; Felix et al., 2009; de Jong et al., 2010b). In addition to maternal 
ethnicity and geographic location, previous studies have reported EA to be associated with maternal 
age {Harris, 1995 #8; Leck, 1968 #25}, multiple gestation {Harris, 1995 #8; Riley, 1998 #24}, 
infant sex {Robert, 1993 #13} and use of assisted reproductive technology {Reefhuis, 2009 #23}. 
In a recent study of EA in the US, women using assisted reproductive technology had a 4.5-fold 
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increased risk of having an infant diagnosed with EA (Reefhuis et al., 2009). Prevalence of EA has 
also been found to be higher among multiple births compared with singletons (Harris et al., 1995; 
Riley et al., 1998), and increased risk was reported with increasing maternal age (Leck et al., 1968; 
Harris et al., 1995). In contrast, a protective effect was found among women who have had three or 
more births (OR 0.50, 95% CI 0.36-0.71) (Harris et al., 1995; Carmichael et al., 2004). However, 
given the low frequency of occurrence of most of these factors in the general population, the 
population attributable risk is likely to be minimal. Variations in ethnicity as detailed above may 
also be surrogates for a number of different exposures, including socioeconomic status, nutrition, 
stress and access to services. Differences in lifestyle factors, such as smoking or dietary habits 
within countries or regional variation may also impact rates. However, lack of temporal trends 
among the included programs suggests environmental factors, which change over time, are less 
likely to play a role in development of EA (Robert et al., 1993; Canfield et al., 2006; Garne et al., 
2007). Underlying genetic susceptibility, biological or physical differences may also modify risk of 
exposures. Although a number of genetic abnormalities have been associated with EA, to date, no 
specific gene has been implicated (Felix et al., 2009). Further studies with more detailed 
information to assess risk factors and underlying characteristics of cases with EA are required. 
 
One of the limitations of the study is that it did not collect information on maternal risk factors that 
might help elucidate the aetiology of EA or explain differences in the prevalence across settings. 
Further, we did not collect information to differentiate between isolated cases and those with 
associated (multiple) or chromosomal anomalies due to difficulties in standardizing the definition of 
associated anomalies across programs. Despite these limitations, one of the strengths of the study is 
that case identification is likely to be complete as EA is diagnosable either antenatally or at the time 
of birth and require surgical attention. Recent studies from the Netherlands and Oxford, UK, 
reported about one third of infants were diagnosed with EA prenatally (38%) (Choudhry et al., 
2007; Garne et al., 2007; de Jong et al., 2010a; Pedersen et al., 2012). Postnatally, EA are suspected 
and diagnosed by respiratory or feeding difficulties and inability to pass a nasogastric tube and 
confirmed on chest x-ray with surgical correction within 24-48 hours (Spitz, 2007). 
 
In conclusion, EA affects, on average 1 in every 4,099 births worldwide and has remained 
surprisingly stable over time. Although there was some variation in the reported prevalence between 
and within countries, overall EA was also relatively consistent across European and American 
surveillance programs. Findings suggest differences in the prevalence observed between programs 
are likely to be attributable to local phenomena affecting reporting and/ or case registration of EA or 
ethnic composition, rather than a real difference in risk occurrence per se. Future epidemiological 
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studies taking into account ethnic distribution, maternal characteristics, genetic factors and 
associated anomalies may provide important information regarding underlying epidemiology of EA. 
 
 
Contributors’ statement 
Pierpaolo Mastroiacovo developed the concept and design of the study. Emanuele Leoncini 
conducted the analysis and drafted the methods. Natasha Nassar was responsible for the drafting of 
the manuscript. All authors provided data for the study and contributed to the interpretation of data 
and had final approval of the manuscript to be published. 
 
Acknowledgements 
We would like to thank Simonetta Zezza for the formatting of the manuscript and liaising with 
contributing members. Elena Szabova would also like to acknowledge Eva Veghova and Daniela 
Brašenova (Slovak Republic) for their skillful support.  
 
 
 12 
References 
 
Bower C, Rudy E, Callaghan A, Cosgrove P, Quick J, Nassar N. 2009. Report of the Birth Defects 
Registry Of Western Australia, 1980-2008. Perth: King Edward Memorial Hospital 
http://www.kemh.health.wa.gov.au/brochures/health_professionals/wnhs0260.pdf. 
Canfield MA, Ramadhani TA, Yuskiv N, Davidoff MJ, Petrini JR, Hobbs CA, Kirby RS, Romitti 
PA, Collins JS, Devine O, Honein MA, Mai CT, Edmonds LD, Correa A. 2006. Improved 
national prevalence estimates for 18 selected major birth defects--United States, 1999-2001. 
MMWR Morb Mortal Wkly Rep 54(51):1301-1305. 
Carmichael SL, Shaw GM, Kaidarova Z. 2004. Congenital malformations in offspring of Hispanic 
and African-American women in California, 1989-1997. Birth Defects Res A Clin Mol 
Teratol 70(6):382-388. 
Castilla EE, Orioli IM. 2004. ECLAMC: the Latin-American collaborative study of congenital 
malformations. Community Genet 7(2-3):76-94. 
Choudhry M, Boyd PA, Chamberlain PF, Lakhoo K. 2007. Prenatal diagnosis of tracheo-
oesophageal fistula and oesophageal atresia. Prenat Diagn 27(7):608-610. 
Clark DC. 1999. Esophageal atresia and tracheoesophageal fistula. Am Fam Physician 59(4):910-
916, 919-920. 
Cocchi G, Gualdi S, Bower C, Halliday J, Jonsson B, Myrelid A, Mastroiacovo P, Amar E, Bakker 
MK, Correa A, Doray B, Melve KK, Koshnood B, Landau D, Mutchinick OM, Pierini A, 
Ritvanen A, Ruddock V, Scarano G, Sibbald B, Sipek A, Tenconi R, Tucker D, Anneren G. 
2010. International trends of Down syndrome 1993-2004: Births in relation to maternal age 
and terminations of pregnancies. Birth Defects Res A Clin Mol Teratol 88(6):474-479. 
Correa-Villasenor A, Cragan J, Kucik J, O'Leary L, Siffel C, Williams L. 2003. The Metropolitan 
Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for 
Disease Control and Prevention. Birth Defects Res A Clin Mol Teratol 67(9):617-624. 
Czeizel AE. 1997. First 25 years of the Hungarian congenital abnormality registry. Teratology 
55(5):299-305. 
de Jong EM, de Haan MA, Gischler SJ, Hop W, Cohen-Overbeek TE, Bax NM, de Klein A, 
Tibboel D, Grijseels EW. 2010a. Pre- and postnatal diagnosis and outcome of fetuses and 
neonates with esophageal atresia and tracheoesophageal fistula. Prenat Diagn 30(3):274-
279. 
de Jong EM, Felix JF, de Klein A, Tibboel D. 2010b. Etiology of esophageal atresia and 
tracheoesophageal fistula: "mind the gap". Curr Gastroenterol Rep 12(3):215-222. 
De Vigan C, Khoshnood B, Lhomme A, Vodovar V, Goujard J, Goffinet F. 2005. Prevalence and 
prenatal diagnosis of congenital malformations in the Parisian population: twenty years of 
surveillance by the Paris Registry of congenital malformations. J Gynecol Obstet Biol 
Reprod (Paris) 34(1 Pt 1):8-16. 
Ethen MK, Canfield MA. 2002. Impact of including elective pregnancy terminations before 20 
weeks gestation on birth defect rates. Teratology 66 Suppl 1:S32-35. 
Feldkamp M, Macleod L, Young L, Lecheminant K, Carey JC. 2005. The methodology of the Utah 
Birth Defect Network: congenital heart defects as an illustration. Birth Defects Res A Clin 
Mol Teratol 73(10):693-699. 
Felix JF, de Jong EM, Torfs CP, de Klein A, Rottier RJ, Tibboel D. 2009. Genetic and 
environmental factors in the etiology of esophageal atresia and/or tracheoesophageal fistula: 
an overview of the current concepts. Birth Defects Res A Clin Mol Teratol 85(9):747-754. 
Forrester MB, Merz RD. 2005. Epidemiology of oesophageal atresia and tracheo-oesophageal 
fistula in Hawaii, 1986-2000. Public Health 119(6):483-488. 
Garne E, Loane M, Dolk H. 2007. Gastrointestinal malformations: impact of prenatal diagnosis on 
gestational age at birth. Paediatr Perinat Epidemiol 21(4):370-375. 
Genevieve D, de Pontual L, Amiel J, Sarnacki S, Lyonnet S. 2007. An overview of isolated and 
syndromic oesophageal atresia. Clin Genet 71(5):392-399. 
 13 
Gunnarsdottir A, Bjarnason G, Haraldsson A. 2004. Oesophageal atresia in Iceland 1963-2002; 
Incidence outcome. Laeknabladid 90(9):629-633. 
Haeusler MC, Berghold A, Stoll C, Barisic I, Clementi M. 2002. Prenatal ultrasonographic 
detection of gastrointestinal obstruction: results from 18 European congenital anomaly 
registries. Prenat Diagn 22(7):616-623. 
Harris J, Kallen B, Robert E. 1995. Descriptive epidemiology of alimentary tract atresia. Teratology 
52(1):15-29. 
ICBDSR International Clearinghouse for Birth Defects Surveillance and Research. 2008. Annual 
Report 2008. Rome, ICBDSR Centre. 
Leck I, Record RG, McKeown T, Edwards JH. 1968. The incidence of malformations in 
Birmingham, England, 1950-1959. Teratology 1(3):263-280. 
Leoncini E, Baranello G, Orioli IM, Anneren G, Bakker M, Bianchi F, Bower C, Canfield MA, 
Castilla EE, Cocchi G, Correa A, De Vigan C, Doray B, Feldkamp ML, Gatt M, Irgens LM, 
Lowry RB, Maraschini A, Mc Donnell R, Morgan M, Mutchinick O, Poetzsch S, Riley M, 
Ritvanen A, Gnansia ER, Scarano G, Sipek A, Tenconi R, Mastroiacovo P. 2008. Frequency 
of holoprosencephaly in the International Clearinghouse Birth Defects Surveillance 
Systems: searching for population variations. Birth Defects Res A Clin Mol Teratol 
82(8):585-591. 
Leoncini E, Botto LD, Cocchi G, Anneren G, Bower C, Halliday J, Amar E, Bakker MK, Bianca S, 
Canessa Tapia MA, Castilla EE, Csaky-Szunyogh M, Dastgiri S, Feldkamp ML, Gatt M, 
Hirahara F, Landau D, Lowry RB, Marengo L, McDonnell R, Mathew TM, Morgan M, 
Mutchinick OM, Pierini A, Poetzsch S, Ritvanen A, Scarano G, Siffel C, Sipek A, Szabova 
E, Tagliabue G, Vollset SE, Wertelecki W, Zhuchenko L, Mastroiacovo P. 2010. How valid 
are the rates of Down syndrome internationally? Findings from the International 
Clearinghouse for Birth Defects Surveillance and Research. Am J Med Genet A 
152A(7):1670-1680. 
Lowry RB, Sibbald B, Wang FL. 2009. Alberta Health andWellness. 2007. Congenital Anomalies 
Surveillance System: Seventh Report, 1980–2005. Edmonton, AB: Alberta Health and 
Wellness. 
Mutchinick O, Lisker R, Babinski V. 1988. The Mexican program of Registration and 
Epidemiologic Surveillance of External Congenital Malformations. Salud Publica Mex 
30(1):88-100. 
NBDPN National Birth Defects Prevention Network. 2008.State Birth Defects Surveillance 
Program Directory. Birth Defects Research (Part A) 82:906 961. 
NBDPN National Birth Defects Prevention Network. 2009. Population-based Birth Defects 
Surveillance data from selected states, 2002-2006. Birth Defects Res A Clin Mol Teratol 
85(12):939-1055. 
Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, Anderson P, Mason CA, Collins 
JS, Kirby RS, Correa A. 2010. Updated National Birth Prevalence estimates for selected 
birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol 
88(12):1008-1016. 
Pedersen RN, Calzolari E, Husby S, Garne E., EUROCAT Working Group. 2012. Oesophageal 
atresia: prevalence, prenatal diagnosis and associated anomalies in 23 European regions. 
Arch Dis Child. 97(3):227-32 
Rankin J, Pattenden S, Abramsky L, Boyd P, Jordan H, Stone D, Vrijheid M, Wellesley D, Dolk H. 
2005. Prevalence of congenital anomalies in five British regions, 1991-99. Arch Dis Child 
Fetal Neonatal Ed 90(5):F374-379. 
Reefhuis J, Honein MA, Schieve LA, Correa A, Hobbs CA, Rasmussen SA. 2009. Assisted 
reproductive technology and major structural birth defects in the United States. Hum Reprod 
24(2):360-366. 
Riley MM, Halliday JL, Lumley JM. 1998. Congenital malformations in Victoria, Australia, 1983-
95: an overview of infant characteristics. J Paediatr Child Health 34(3):233-240. 
 14 
Robert E, Mutchinick O, Mastroiacovo P, Knudsen LB, Daltveit AK, Castilla EE, Lancaster P, 
Kallen B, Cocchi G. 1993. An international collaborative study of the epidemiology of 
esophageal atresia or stenosis. Reprod Toxicol 7(5):405-421. 
SAS. 2008. SAS/STAT Software. SAS institute Inc., Cary, NC 
Shaw-Smith C. 2006. Oesophageal atresia, tracheo-oesophageal fistula, and the VACTERL 
association: review of genetics and epidemiology. J Med Genet 43(7):545-554. 
Sparey C, Jawaheer G, Barrett AM, Robson SC. 2000. Esophageal atresia in the Northern Region 
Congenital Anomaly Survey, 1985-1997: prenatal diagnosis and outcome. Am J Obstet 
Gynecol 182(2):427-431. 
Spitz L. 2007. Oesophageal atresia. Orphanet J Rare Dis 2:24. 
Stata. 2007. Data Analysis and Statistical Software, Release 10, Stata Corp LP 
Stoll C, Alembik Y, Dott B, Roth MP. 2009. Associated malformations in patients with esophageal 
atresia. Eur J Med Genet 52(5):287-290. 
Torfs CP, Curry CJ, Bateson TF. 1995. Population-based study of tracheoesophageal fistula and 
esophageal atresia. Teratology 52(4):220-232. 
 
 
 15 
Table 1: Characteristics of eighteen surveillance programs of the International Clearinghouse for Birth Defects 
Surveillance and Research (ICBDSR) reporting on esophageal atresia  
 
Surveillance Programs Coverage ETOPFA 
Maximum age or source 
of ascertainment or 
registration 
Source of 
ascertainment of live 
births, stillbirths and 
ETOPFA 
Criteria defining 
stillbirths  
Australia Western Australia PP1 P, R 6 years M 20 wks or 400 g  
Canada Alberta RP P, R 1 year M 20 wks or 500 g  
Czech Republic RP P, R 15 years M 28 wks or 1,000 g  
France Paris PP1 P, R Hospital Discharge M 22 wks  
France Central East RP P, R 18 months M 22 wks  
Germany Saxony–Anhalt PP2 P, R 1 year M 500 g  
Hungary RP P, R 1 year M 24 wks or 500 g  
Ireland Dublin RP NP 5 years M 24 wks or 500 g  
Israel H P, R 3-7 days S 20 wks or 500 g  
Italy Emilia Romagna PP1 P, R 1 week S 180 days  
Mexico H NP Hospital Discharge S 20 wks or 500 g  
Northern Netherlands RP P, R 15 years M 24 wks  
Slovak Republic PP1 P, R 1 year S 28 wks or 1,000 g  
South America H NP Hospital Discharge S 500 g  
USA Atlanta RP P, R 6 years M 20 wks  
USA Texas RP P, R 1 year M 20 wks (*)  
USA Utah RP P, R 5 years M 20 wks  
Wales RP P, R 1 year M 24 wks  
Coverage: RP=resident population (includes only cases born to mothers residing in the area covered by the registry during pregnancy, 
despite where the delivery took place, and excluding all cases born to non-resident mothers that delivered in the area covered by the 
registry). PP1=present population (includes all cases born to mothers that delivered in the area covered by the registry, regardless of 
where they were residing during pregnancy. The registry does not cover cases born outside the area, even if the mother is resident in the 
area). PP2=present population (excludes subjects born to mothers that delivered in the area covered by the registry but were residing out 
of the area. The registry does not cover cases born outside the area even if the mother is residing in the area. H=hospital-based (includes 
only a proportion - even near to 99% - of all subjects delivered in the area covered by the registry). 
ETOPFA (= elective terminations of pregnancy for a fetal anomaly): P=permitted by country’s legislation; NP=not permitted; 
R=reported; NR=not reported 
Source of ascertainment: S=Single source; M=Multiple sources 
Stillbirths: wks=weeks; (*) Before 2001: 20 weeks. Since 2001: All stillbirths with documented birth defects included 
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Table 2: Prevalence of esophageal atresia among eighteen surveillance programs of the International 
Clearinghouse for Birth Defects Surveillance and Research (ICBDSR), 1998-2007, ordered by increasing 
prevalence 
 
 
Surveillance Program Total Births 
EA with 
TEF 
EA 
without 
TEF 
Unspecified 
atresia, 
fistula or 
stenosis 
Total 
cases 
Prevalence                           
(per 10.000 births) 95% CI 
Hungary 970,828 25 147 0 172 1.77 1.52 2.06 
USA Atlanta 513,272 71 20 0 91 1.77 1.43 2.18 
USA Texas *† 3,305,512 495 102 0 597 1.81 1.66 1.96 
Canada Alberta 404,595 66 13 0 79 1.95 1.55 2.43 
Slovak Republic† 371,644 45 35 0 80 2.15 1.71 2.68 
France Paris 363,914 72 8 0 80 2.20 1.74 2.74 
Germany Saxony–Anhalt 162,723 24 14 0 38 2.34 1.65 3.21 
USA Utah† 453,129 100 11 0 111 2.45 2.02 2.95 
Ireland Dublin 227,586 55 2 0 57 2.50 1.90 3.24 
Czech Republic 969,144 169 82 0 251 2.59 2.28 2.93 
Australia Western 262,338 65 4 0 69 2.63 2.05 3.33 
Mexico 264,415 31 41 0 72 2.72 2.13 3.43 
Wales 323,462 78 11 0 89 2.75 2.21 3.39 
France Central East 956,012 137 130 0 267 2.79 2.47 3.15 
Italy Emilia Romagna 288,155 64 17 2 83 2.88 2.29 3.57 
Northern Netherlands 195,100 49 12 1 62 3.18 2.44 4.07 
Israel 208,782 0 0 74 74 3.54 2.78 4.45 
South America 1,822,848 474 100 97 671 3.68 3.41 3.97 
                  
TOTAL 12,063,459 2,020 749 174 2,943 2.44 2.35 2.53 
 
 
EA = Esophageal atresia; TEF = tracheo-esophageal fistula 
EA with TEF (ICD9-BPA: 750.31, 750.33; ICD10: Q39.1); EA without TEF (ICD9-BPA: 750.30; ICD10: Q39.0); unspecified 
atresia, fistula or stenosis (ICD9-BPA: 750.3; no corresponding ICD10 codes).  
* Includes a few cases of possible/probable diagnosed cases 
† Years available: Slovak Republic 2001-2007, USA Utah 1999-2007, USA Texas 1998-2006 
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Figure 1: Proportion of esophageal atresia among eighteen surveillance programs members of 
the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR), by 
pregnancy outcome, 1998-2007  
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ETOPFA = elective termination of pregnancy for fetal anomaly 
